Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, Civeira F, Hernández A, da Silva PM, Rodriguez-Botaro A, Zambón D, Lima J, Díaz C, Aristegui R, Sol JM, Chaves J, Hernández G; ATOMIX Investigators. Gómez-Gerique JA, et al. Among authors: mostaza jm. Atherosclerosis. 2002 Jun;162(2):245-51. doi: 10.1016/s0021-9150(01)00708-0. Atherosclerosis. 2002. PMID: 11996943 Clinical Trial.
Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X. Lahoz C, et al. Among authors: mostaza jm. Metabolism. 2005 Jun;54(6):741-7. doi: 10.1016/j.metabol.2004.12.020. Metabolism. 2005. PMID: 15931608 Clinical Trial.
Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study).
Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, Civeira F, Hernández A, Marqués da Silva P, Rodriguez-Botaro A, Zambón D, Lima J, Gómez-Gerique JA, Díaz C, Arístegui R, Sol JM, Hernández G. Ros E, et al. Among authors: mostaza jm. Clin Drug Investig. 2003;23(3):153-65. doi: 10.2165/00044011-200323030-00002. Clin Drug Investig. 2003. PMID: 23340922
[Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society].
Pedro-Botet J, Mostaza JM, Pintó X, Banegas JR; En Nombre del Grupo de Investigadores EDICONDIS-ULISEA. Pedro-Botet J, et al. Among authors: mostaza jm. Clin Investig Arterioscler. 2013 Sep-Oct;25(4):155-63. doi: 10.1016/j.arteri.2013.07.006. Epub 2013 Sep 14. Clin Investig Arterioscler. 2013. PMID: 24041476 Spanish.
Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
Masana L, Ibarretxe D, Rodríguez-Borjabad C, Plana N, Valdivielso P, Pedro-Botet J, Civeira F, López-Miranda J, Guijarro C, Mostaza J, Pintó X; Expert group from the Spanish Arteriosclerosis Society. Masana L, et al. Atherosclerosis. 2019 Aug;287:89-92. doi: 10.1016/j.atherosclerosis.2019.06.905. Epub 2019 Jun 20. Atherosclerosis. 2019. PMID: 31238171 Free article. Review.
Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease.
Pedro-Botet J, López-Miranda J, Badimón L, Civeira F, Guijarro C, Millán J, Mostaza JM, Pintó X, Valdivielso P, Masana L; Expert group from the Spanish Arteriosclerosis Society. Pedro-Botet J, et al. Among authors: mostaza jm. Am J Cardiovasc Drugs. 2020 Aug;20(4):325-332. doi: 10.1007/s40256-019-00376-y. Am J Cardiovasc Drugs. 2020. PMID: 31650523 Review.
153 results